Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Advanced, EGFR-positive NSCLC

• ECOG Performance Status 0, 1 or 2

• Measurable disease

Exclusion Criteria:

• Known CNS metastasis

• Pre-existing autoimmune or antibody mediated disease